CDT Equity Inc.
NCM: CDTLive Quote
📈 ZcoreAI Score
Our AI model analyzes CDT Equity Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CDT Z-Score →About CDT Equity Inc.
Healthcare
Biotechnology
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
📊 Fundamental Analysis
CDT Equity Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
At a current price of $4.08, CDT currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $3.64 - $3030.00).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$19.27M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
2.08
52W High
$3,030.00
52W Low
$3.64
Avg Volume
73K
Day High
Day Low